# Uniphar plc (UPR.L) fundamentals

Data as of 2026-09-08. LSE, United Kingdom. Sector: Healthcare / Health Care Equipment & Supplies. Price 358p, market value 954 millionp.

## Valuation
- **P/E (trailing): 21.1×** (5-yr avg 1507.2×, 3-yr avg 1228.6×). Uniphar plc trades at 21.1× trailing earnings, well below its own five-year average of 1507.2×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 15.1×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 0.2×**. Each dollar of revenue is priced at 0.2×, a low multiple typical of thin-margin businesses or out-of-favour stocks.
- **Price / book: 2.6×**. The shares trade at 2.6× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 5.5×**. Enterprise value is 5.5× operating earnings before depreciation, the multiple that ignores how the company is financed; below 8× is inexpensive for most sectors.
- **Free-cash-flow yield: 11.6%** (5-yr avg 0.1%). Free cash flow equals 11.6% of the market value, above its five-year average of 0.1%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.
- **Earnings yield: 4.7%**. The inverse of the P/E: 4.7% of the price is earned each year.

## Profitability
- **Gross margin: 15.1%**. Uniphar plc keeps 15.1% of revenue after the direct cost of what it sells, a thin margin typical of retail, distribution and commodity businesses.
- **Operating margin: 2.9%**. 2.9% of revenue is left after running the business, which leaves little cushion in a downturn.
- **Net margin: 1.7%**. 1.7% of each dollar of sales reaches the bottom line.
- **Return on equity: 12.6%**. 12.6% on shareholders' equity is solid.
- **Return on invested capital: 19.0%**. Return on all capital, debt included, is 19.0%: comfortably above what that capital costs.
- **Return on assets: 6.7%**. Each dollar of assets produces 6.7% of profit.

## Growth
- **Revenue growth (1 yr): 10.9%** (3-yr 14.1%/yr, 5-yr 11.0%/yr). Revenue grew 10.9% over the last year, against 11.0% a year compounded over five years.
- **EPS growth (1 yr): -20.8%** (3-yr 3.8%/yr, 5-yr 11.6%/yr). Earnings per share fell 20.8%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): 10.5%/yr**. Free cash flow has compounded at 10.5% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 1.27**. Debt is 1.27 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Net debt / EBITDA: 1.2×**. It would take 1.2 years of operating earnings to repay net borrowings, within the comfortable range.
- **Interest coverage: 3.7×**. Operating profit covers interest 3.7× over, a safe margin.
- **Current ratio: 0.99** (quick 0.64). Current liabilities exceed current assets, so the company depends on ongoing cash generation or refinancing to pay the next year's bills.
- **Altman Z-score: 2.70**. A Z-score of 2.70 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 0.50%** (0p per share, trailing). Uniphar plc yields 0.50%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 10%** (8% of free cash flow). 10% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 3**. 3 straight years of increases.
- **Dividend growth (5 yr): 21.8%/yr** (1-yr 5.4%). The dividend has compounded at 21.8% a year over five years, doubling roughly every 3 years at that pace.
- **Shareholder yield: 3.7%**. Dividends plus net buybacks return 3.7% of the market value a year.

## Price and momentum
- **Total return (1 yr): 0.3%** (YTD 18.7%, 3-mo -14.3%). The shares are up 0.3% over twelve months including dividends.
- **From 52-week high: -16.4%** (21.8% above the low). Trading 16% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 32**. An RSI of 32 is neutral.
- **Beta (1 yr): 0.20** (volatility 23%). Beta of 0.20 against the FTSE All-Share: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=UPR.L · Page: https://foliofundamentals.com/stocks/upr.l

Not investment advice.